Question about Galapagos?
We hope we answer it below.
We are a biotechnology company with operations in Europe and the U.S. dedicated to developing transformational medicines for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules, CAR-T therapies, and biologics in oncology and immunology. With capabilities from lab to patient, including a decentralized, point-of-care CAR-T manufacturing network, we are committed to challenging the status quo and delivering results for our patients, employees and shareholders. More information is available in our company fact sheet and brochure.
Galapagos was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. Please see Our Story for more on this.
Galapagos is headquartered in Mechelen, Belgium and has facilities throughout Europe and in the US. Addresses and contact info here.
We post our Annual CSR report on our Sustainability section. Scroll down to the bottom of the page for the Reports.
Contact us, and we will reach out to you as soon as possible.